Welcome to our dedicated page for Gh Research Plc news (Ticker: GHRS), a resource for investors and traders seeking the latest updates and insights on Gh Research Plc stock.
GH Research Plc (GHRS) is a clinical-stage biopharmaceutical company pioneering novel therapies for treatment-resistant depression. This page provides centralized access to all official press releases, clinical trial updates, and financial disclosures, offering stakeholders a reliable resource for tracking the company’s progress.
Investors and researchers will find timely updates on mebufotenin-based drug development, including inhalable and intravenous formulations in clinical testing. The page aggregates announcements on regulatory milestones, research partnerships, and quarterly financial results, ensuring comprehensive coverage of GH Research’s advancements in mental health therapeutics.
Bookmark this page or check back regularly to stay informed about GHRS’s innovative approaches to addressing unmet needs in depression treatment. All content is sourced directly from the company to maintain accuracy and compliance with financial reporting standards.
GH Research has completed enrollment for its Phase 2b trial of GH001 (inhaled mebufotenin) in treatment-resistant depression, with top-line data expected by Q1 2025. The company reported $193.8 million in cash and equivalents as of September 30, 2024, down from $222.7 million at end-2023. Q3 2024 saw increased R&D expenses of $8.4 million (vs $7.1M in Q3 2023) and G&A expenses of $4.2 million (vs $2.6M in Q3 2023), resulting in a net loss of $12.1 million ($0.23 per share). The FDA clinical hold on GH001's IND continues, with ongoing nonclinical studies addressing inhalation toxicology concerns.
GH Research PLC (Nasdaq: GHRS) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Phase 2b trial of GH001 for treatment-resistant depression (TRD) on track for completion in Q3 2024.
2. Phase 1 trial for proprietary aerosol delivery device approved in the UK and recruiting.
3. Cash position of $204.5 million as of June 30, 2024.
4. R&D expenses increased to $9.8 million in Q2 2024 from $7.2 million in Q2 2023.
5. Net loss of $10.4 million ($0.20 per share) in Q2 2024 compared to $7.7 million ($0.15 per share) in Q2 2023.
6. FDA clinical hold on GH001 IND continues, with ongoing nonclinical studies to address inhalation toxicology concerns.
GH Research PLC (Nasdaq: GHRS) has announced the promotion of Dr. Velichka "Villy" Valcheva to Chief Executive Officer, succeeding co-founder PD Dr. med. Theis Terwey. Dr. Valcheva, who joined the company in August 2023 and has served as Chief Medical Officer since February 2024, brings over 20 years of pharmaceutical and biotech industry leadership experience.
The company is currently screening patients for its phase 2b trial in treatment-resistant depression, with enrollment expected to complete in September 2024. Additionally, a phase 1 healthy volunteer study using GH Research's proprietary device is actively enrolling in the UK. These developments signify the company's progress in its mission to transform the treatment of psychiatric and neurological disorders.
GH Research PLC reported financial results for Q1 2024, with cash reserves of $214.0 million expected to last until 2026. The Phase 2b trial of GH001 for treatment-resistant depression is progressing, with top-line data expected in late 2024. GH002, the intravenous product candidate, showed promising results in a Phase 1 trial. The company provided updates on IND for GH001 and financial highlights.
FAQ
What is the current stock price of Gh Research Plc (GHRS)?
What is the market cap of Gh Research Plc (GHRS)?
